Medicine and Dentistry
Malignant Neoplasm
96%
Human immunodeficiency virus
40%
Hepatitis C Virus
24%
COVID-19
24%
HIV Test
18%
Central Venous Catheter
16%
Infection
15%
Cancer Therapy
15%
Catheter Infection
14%
Infectious Disease
12%
Mycosis
12%
Glyceryl Trinitrate
12%
Prospective Cohort Study
12%
Oncology
12%
Immunotherapy
11%
Human Immunodeficiency Virus Infection
11%
Severe Acute Respiratory Syndrome Coronavirus 2
10%
Diseases
9%
Cancer Treatment
8%
Systemic Mycosis
8%
Odds Ratio
8%
Hematologic Malignancy
7%
Observational Study
6%
Chimeric Antigen Receptor T-Cell Immunotherapy
6%
Overall Survival
6%
Emergency Department
6%
Telavancin
6%
Seasonal Influenza
6%
Bloodstream Infection
6%
4 Iodo 2,5 Dimethoxyamphetamine
6%
Lung
6%
Encephalitis
6%
Quinolone
6%
Sofosbuvir
6%
False Positive Result
6%
Gastrointestinal Infection
6%
Acanthamoeba Infection
6%
Gram-Negative Bacteria
6%
Nucleic Acid Amplification
6%
Hepatitis B
6%
Cancer Immunotherapy
6%
Hospital Infection
6%
Patient with Human Immunodeficiency Virus
6%
Antiviral Therapy
6%
Postcovid Syndrome
6%
Diffuse Large B-Cell Lymphoma
6%
Integrase
6%
Influenza A (H1N1)
6%
Health Care Provider
6%
Stereotypic Movement Disorder
6%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Hepatitis C Virus
31%
HIV
31%
Diseases
24%
Bloodstream Infection
12%
Immune Checkpoint Inhibitor
12%
Infection
11%
Hematologic Malignancy
11%
Adverse Event
10%
Solid Malignant Neoplasm
9%
Catheter Infection
8%
Observational Study
8%
Chronic Hepatitis C
8%
Systemic Mycosis
7%
Antiviral Drug
7%
Hepatitis B
6%
Hepatitis B Virus
6%
Renin
6%
Meropenem
6%
Urinary Tract Infection
6%
Telavancin
6%
Glyceryl Trinitrate
6%
Seasonal Influenza
6%
Prospective Cohort Study
6%
Quinolone
6%
Integrase
6%
Galactomannan
6%
Tablet
6%
Transgenic Mouse
6%
Acanthamoeba Infection
6%
Virus Hepatitis
6%
Cefepime
6%
Coronavirinae
6%
Angiotensinogen
6%
Biological Marker
6%
Mycosis
6%
Eclampsia
6%
Doxycycline
6%
Immunotherapy
6%
Gram Negative Bacterium
6%
Sofosbuvir
6%
Invasive Aspergillosis
6%
Influenza A (H1N1)
6%
Posaconazole
6%
Pandemic Influenza
6%
Hexachlorophene
6%
Antiviral Therapy
5%
RNA Directed DNA Polymerase Inhibitor
5%
Keyphrases
Cancer Patients
47%
In Cancer
43%
Hepatitis C Virus
28%
Patients with Cancer
18%
Cancer Treatment
13%
Human Immunodeficiency Virus Testing
12%
Tertiary Cancer Center
12%
Hepatitis C Virus Screening
12%
AIDS/HIV
12%
Infected Patients
10%
SVR12
8%
MD Anderson Cancer Center
8%
Sustained Virological Response
8%
Antiretroviral Therapy
8%
Prospective Observational Study
8%
Invasive Fungal Infection
8%
Clinical Outcomes
7%
Acute Hepatitis C
7%
Immune Checkpoint Inhibitors
7%
Adult Patients
7%
Human Immunodeficiency Virus Infection
7%
Cancer Therapy
6%
Risk Factors
6%
Malignancy
6%
Gram-negative Bacilli Bacteremia
6%
Fungal Infection
6%
False Reactive
6%
Hypertensive Disorders
6%
Intravenous Formulation
6%
Fungal Biomarkers
6%
Survivorship
6%
Genetic Basis
6%
Integrase Strand Transfer Inhibitor (INSTI)
6%
Disinformation
6%
Practical Guide
6%
Treatment Modalities
6%
Healthcare
6%
Gram-positive
6%
Center Experience
6%
Risk Treatment
6%
Emergency Department
6%
Transgenic
6%
Galactomannan
6%
Antibiotic-free
6%
30-day Mortality
6%
Influenza in children
6%
International multicenter Study
6%
Gene-targeted Mice
6%
Catheter-related Bloodstream Infection (CRBSI)
6%
Tablet Formulation
6%